SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MCAR
MCAR 0.0650-36.3%Jan 31 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richroni who wrote (158)3/27/1998 5:54:00 PM
From: Andrew Q. Viet  Read Replies (1) of 467
 
since MCAR trades on the bulletin board, it needs to report once every 6 months. However, they are in the process of waiting for Nasdaq listing approval.

Their treatment systems are proprietary, but not patentable, so in theory anyone can duplicate their technologies. But the market is big enough for everyone and it would take a few years for other players to establish their treatment networks. I think once MCAR has the name recognition among urologists, it's very difficult for new players to enter the market.

MCAR positions itself in a clever way by establishing their treatment systems inside doctor's offices. It gives doctors additional incentive to recruit patients, for both MCAR and doctors can benefit from this.

It costs MCAR from $18-22,000 to open each site, so I believe within 2 years MCAR will become entrenched and new players will have a tough time to compete with MCAR in the same market.

MCAR is establishing a connection with most well-known urologists in the country and this will bolster MCAR name recognition.

OFF topic: About the news from PNU:I meant MCAR price impact, not business impact.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext